Management of giant cell arteritis and polymyalgia rheumatica.
Giant cell arteritis and polymyalgia rheumatica are closely related disorders that affect persons more than 50 years of age and cause substantial morbidity. Patients with giant cell arteritis typically have a localized headache, nonspecific systemic symptoms, temporal artery tenderness and a high erythrocyte sedimentation rate (ESR). The diagnosis is confirmed by characteristic pathologic findings on temporal artery biopsy. Patients with polymyalgia rheumatica usually have similar nonspecific systemic symptoms, proximal muscle pain and stiffness, and an elevated ESR. The diagnosis is based on the clinical findings. Both disorders are treated with corticosteroids: high dosages for giant cell arteritis (prednisone in a dosage of 40 to 60 mg per day) and lower dosages for polymyalgia rheumatica (prednisone in a dosage of 10 to 20 mg per day). Symptom relief in response to treatment is rapid and reinforces the diagnosis. After normalization of the ESR, the corticosteroid is tapered, with the patient monitored closely for symptom recurrence. Most patients require corticosteroid therapy for two to three years and experience one or more treatment complications.
Meskimen
S
S
Department of Family and Community Medicine, University of Missouri-Columbia School of Medicine, 65212, USA.
Cook
T D
TD
Blake
R L
RL
D013700:Giant Cell Arteritis / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D006801:Humans; D010353:Patient Education as Topic; D011111:Polymyalgia Rheumatica / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D013664:Teaching Materials; D014481:United States / Q000453:epidemiology